ChiCTR2600123717 版本V1.0 版本创建时间2026/04/29 10:17:20 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600123717 

最近更新日期:

Date of Last Refreshed on:

2026-04-29 10:17:11 

注册时间:

Date of Registration:

2026-04-29 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

乳腺癌患者及其家庭照顾者二元健康干预方案的初步应用

Public title:

Preliminary application of a dyadic health intervention program for breast cancer patients and their family caregivers

注册题目简写:

English Acronym:

研究课题的正式科学名称:

乳腺癌患者及其家庭照顾者二元健康干预方案的初步应用

Scientific title:

Preliminary application of a dyadic health intervention program for breast cancer patients and their family caregivers

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

赵慧慧 

研究负责人:

赵慧慧 

Applicant:

Huihui Zhao 

Study leader:

Huihui Zhao 

申请注册联系人电话:

Applicant telephone:

+86 178 1957 6589

研究负责人电话:

Study leader's telephone:

+86 178 1957 6589

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

495837129@qq.com

研究负责人电子邮件:

Study leader's E-mail:

495837129@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省广州市白云区广州大道北1838号

研究负责人通讯地址:

广东省广州市白云区广州大道北1838号

Applicant address:

No. 1838, Guangzhou Avenue North, Baiyun District, Guangzhou City, Guangdong Province

Study leader's address:

No. 1838, Guangzhou Avenue North, Baiyun District, Guangzhou City, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

510515

研究负责人邮政编码:

Study leader's postcode:

510515

申请人所在单位:

南方医科大学南方医院

Applicant's institution:

Nanfang Hospital, Southern Medical University

研究负责人所在单位:

南方医科大学南方医院

Affiliation of the Leader:

Nanfang Hospital, Southern Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

NFEC-2025-451

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南方医科大学南方医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Nanfang Hospital, Southern Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-05 00:00:00

伦理委员会联系人:

胡兴媛

Contact Name of the ethic committee:

Hu Xingyuan

伦理委员会联系地址:

广东省广州市白云区广州大道北1838号

Contact Address of the ethic committee:

No. 1838, North Guangzhou Avenue, Baiyun District, Guangzhou City, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 6278 7238

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南方医科大学南方医院

Primary sponsor:

Nanfang Hospital, Southern Medical University

研究实施负责(组长)单位地址:

广东省广州市白云区广州大道北1838号

Primary sponsor's address:

No. 1838, North Guangzhou Avenue, Baiyun District, Guangzhou City, Guangdong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

南方医科大学南方医院

具体地址:

广东省广州市白云区广州大道北1838号乳腺科

Institution
hospital:

Nanfang Hospital, Southern Medical University

Address:

No. 1838, North Guangzhou Avenue, Baiyun District, Guangzhou City, Guangdong Province

经费或物资来源:

自筹

Source(s) of funding:

self-financing

Target disease:

Breast cancer

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

对乳腺癌患者及其家庭照顾者进行二元干预,提高生活质量。  

Objectives of Study:

Carry out a binary intervention for breast cancer patients and their family caregivers to improve their quality of life.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.乳腺癌患者纳入标准 (1)经病理学检查确诊为乳腺癌患者; (2)处于治疗期并能在该医院完成全周期的治疗; (3)有家庭照顾者; (4)无认知和交流障碍; (5)知情同意自愿参与本研究者。 2.照顾者纳入标准 (1)年龄≥18岁; (2)住院期间主要负责照护患者并知晓其病情的家庭成员; (3)无认知和交流障碍; (4)知情同意自愿参与本研究。

Inclusion criteria

1.Inclusion Criteria for Breast Cancer Patients (1) Patients diagnosed with breast cancer by pathological examination; (2) Patients undergoing treatment and able to complete the full course of treatment at this hospital; (3) Having a family caregiver; (4) No cognitive or communication disorders; (5) Voluntary participation in this study with signed informed consent. 2.Inclusion Criteria for Caregivers (1) Aged >= 18 years; (2) Family members who are primarily responsible for patient care during hospitalization and are aware of the patient’s condition; (3) No cognitive or communication disorders; (4) Voluntary participation in this study with signed informed consent.

排除标准:

1.乳腺癌患者排除标准 (1)伴有心、肺、肝、肾等重要器官严重疾病,或其他恶性肿瘤的患者; (2)既往有精神障碍或精神病史。 2.照顾者排除标准 罹患重症(包括但不限于恶性肿瘤及重度抑郁等)的家庭照顾者。

Exclusion criteria:

1.Exclusion Criteria for Breast Cancer Patients (1) Patients with severe diseases of vital organs such as the heart, lungs, liver, and kidneys, or other malignant tumors; (2) Patients with a previous history of mental disorders. 2.Exclusion Criteria for Caregivers Family caregivers suffering from serious illnesses (including but not limited to malignant tumors, severe depression, etc.).

研究实施时间:

Study execute time:

From 2026-05-01 00:00:00 To 2026-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-01 00:00:00 To 2026-08-31 00:00:00  

干预措施:

Interventions:

组别:

干预组

样本量:

30

Group:

Intervention group

Sample size:

干预措施:

二元干预

干预措施代码:

Intervention:

Bivariate intervention

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

usual care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东 

市(区县):

 

Country:

China 

Province:

Guangdong 

City:

 

单位(医院):

南方医科大学南方医院 

单位级别:

三甲 

Institution
hospital:

Nanfang Hospital, Southern Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

生活质量

指标类型:

主要指标

Outcome:

quality of life

Type:

Primary indicator

测量时间点:

干预前(T0)、干预后即刻(T1)、干预结束后1个月(T2)

测量方法:

生活质量测定量表简表

Measure time point of outcome:

Before intervention (T0), immediately after intervention (T1), and 1 month after the end of intervention (T2)

Measure method:

Quality of Life Scale-Short Form

指标中文名:

应对方式

指标类型:

次要指标

Outcome:

coping strategies

Type:

Secondary indicator

测量时间点:

干预前(T0)、干预后即刻(T1)、干预结束后1个月(T2)

测量方法:

简易应对方式问卷

Measure time point of outcome:

Before intervention (T0), immediately after intervention (T1), and 1 month after the end of intervention (T2)

Measure method:

Simplified Coping Style Questionnaire

指标中文名:

沟通程度

指标类型:

次要指标

Outcome:

Level of Communication

Type:

Secondary indicator

测量时间点:

干预前(T0)、干预后即刻(T1)、干预结束后1个月(T2)

测量方法:

家庭回避癌症沟通量表

Measure time point of outcome:

Before intervention (T0), immediately after intervention (T1), and 1 month after the end of intervention (T2)

Measure method:

Family Avoidance of Communication about Cancer Scale

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由赵慧慧通过SPSS软件生成随机数字表。

Randomization Procedure (please state who generates the random number sequence and by what method):

The random sequence was generated by Zhao Huihui using SPSS software.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

本研究对资料收集实施盲法。由于研究干预方法的特性,无法对干预人员及研究对象施盲,但对这两类人群将对本研究假设实施遮敝,以减少实施偏倚的风险。

Blinding:

This study adopted blinding for data collection. Due to the nature of the intervention, it was not feasible to blind the intervention providers or the study participants; however, both groups were masked to the study hypotheses to reduce the risk of performance bias.

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

ED

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-29 10:17:11